• Home

  • HEALTH CARE

  • HEALTHY LIFESTYLE

  • HYGIENE

  • COSMETICS

  • FOR HIM

  • PREGNANCY AND MOTHERHOOD

  • CHILD

    2. HEALTH CARE
    3. Keppra 500mg 60 tablets — Made in Belgium — Free Delivery

    Keppra 500mg 60 tablets — Made in Belgium — Free Delivery


    Brand: UCB Pharma S. A.
    Product Code: Keppra
    Availability: In Stock
    $56.53
    Add to Cart

    Product description 

    Keppra® tablets are used for the following indications:
    • monotherapy (preparation of first choice) in the treatment of: partial seizures with or without secondary generalization in adults and adolescents aged 16 years and over who are newly diagnosed with epilepsy;
    • as an additional therapy in the treatment of:
    • partial seizures with or without secondary generalization in adults, adolescents and children over 6 years of age with epilepsy;
    • myoclonic seizures in adults and adolescents from 12 years of age with juvenile myoclonic epilepsy;
    • primary generalized convulsive (tonic-clonic) seizures in adults and adolescents over 12 years of age with idiopathic generalized epilepsy.

    Compound

    The active substance is levetiracetam (one tablet contains 500 mg levetiracetam).
    Excipients: croscarmellose sodium, macrogol 6000, anhydrous colloidal silicon dioxide, magnesium stearate.
    Film coating: Opadry 85F32004: polyvinyl alcohol, titanium dioxide (E 171), macrogol 3350, talc, iron oxide yellow (E172).

    Contraindications

    Hypersensitivity to levetiracetam or other pyrrolidone derivatives, as well as to any excipients of the preparation.

    Mode of application

    Tablets should be taken orally with a sufficient amount of liquid, with or without food. When taken orally, levetiracetam may have a bitter taste. Divide the daily dose into two equal doses.
    Monotherapy
    Adults and teenagers over the age of 16. Monotherapy in adults and children over 16 years of age should begin with the recommended dose of 500 mg/day (250 mg 2 times a day) followed by an increase in the initial therapeutic dose to 1000 mg/day (up to 500 mg 2 times a day) after two weeks. It is possible to increase the dose by 500 mg / day (250 mg 2 times a day) every two weeks, depending on the clinical effect. The maximum daily dose is 3000 mg / day (1500 mg 2 times a day).
    Children and teenagers under the age of 16. The safety and efficacy of Keppra® in children and adolescents under 16 years of age as monotherapy have not been established. No data available.
    Complementary Therapy
    Adjunctive therapy for adults (≥ 18 years of age) and adolescents (aged 12 to 17 years) weighing 50 kg or more. The initial therapeutic dose is 1000 mg / day (500 mg 2 times a day). This is the starting dose given on the first day of treatment. Depending on the clinical picture and tolerability of the preparation, the daily dose can be increased to a maximum of 3000 mg / day (1500 mg 2 times a day). Dose adjustments of 1000 mg/day (500 mg twice daily) can be made every 2 to 4 weeks.
    Additional therapy for children from 6 years of age and adolescents (aged 12 to 17 years) weighing less than 50 kg. The lowest effective dose should be used. The initial dose for a child or adolescent weighing 25 kg should be 250 mg twice a day, the maximum dose is 750 mg twice a day. For children weighing more than 50 kg, doses are prescribed according to the scheme given for adults. For infants and children under 6 years of age, it is advisable to use Keppra® in the form of an oral solution.

    Application features

    pregnant
    Special advice should be given to women of reproductive age. Treatment with levetiracetam should be reconsidered if a woman is planning a pregnancy. As with all antiepileptic preparations, abrupt withdrawal of levetiracetam should be avoided as this may lead to a seizure attack, which may have serious consequences for the woman and the unborn child. Monotherapy should be preferred whenever possible, as treatment with multiple antiepileptic preparations may be associated with a higher risk of birth defects than with monotherapy, depending on the preparation combination.
    Levetiracetam may be used during pregnancy if, after careful evaluation, it is considered clinically necessary. In this case, it is recommended to use the lowest effective dose.
    Levetiracetam passes into a woman's breast milk. Therefore, breastfeeding is not recommended. However, if levetiracetam is to be used during breastfeeding, the benefits and risks of treatment should be weighed against the importance of breastfeeding.
    There was no effect on reproductive function in animal studies. The potential risk to humans is unknown because there are no clinical data available.
    Children
    The physician should prescribe the most appropriate dosage form, dosage and form of release, depending on age, body weight and the calculated dose.
    The preparation in the form of tablets is not recommended for use in children under the age of 6 years.
    Drivers
    Levetiracetam slightly or moderately affects the ability to drive vehicles and work with other mechanisms. Due to possible individual sensitivity, some patients may experience drowsiness or other symptoms associated with effects on the central nervous system, especially at the beginning of treatment or during dose increases. Therefore, such patients should be careful when engaging in activities that require increased concentration of attention, such as driving a car or operating machinery. Patients are advised to refrain from driving vehicles or operating other mechanisms until it has been established that their ability to engage in such activity is not disturbed.

    Overdose

    Symptoms
    With an overdose of Keppra®, drowsiness, agitation, aggression, respiratory depression, depression of consciousness, and coma were observed.
    Treatment
    In case of acute overdose, it is necessary to wash the stomach or induce vomiting. There is no specific antidote for levetiracetam. If necessary, carry out symptomatic treatment, including using hemodialysis (up to 60% of levetiracetam and 74% of the main metabolite are excreted).

    Side effects

    The most commonly reported adverse reactions were nasopharyngitis, drowsiness, headache, fatigue and dizziness.

    Storage conditions

    Store in the original packaging at a temperature not exceeding 25°C, out of the reach of children.
    Shelf life - 3 years.

    There are no reviews for this product.
    VEV Healthcare Store © 2017